Moors & Cabot’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-16,000
| Closed | -$14K | – | 711 |
|
|
2019
Q4 | $14K | Hold |
16,000
| – | – | ﹤0.01% | 604 |
|
|
2019
Q3 | $9K | Hold |
16,000
| – | – | ﹤0.01% | 648 |
|
|
2019
Q2 | $8K | Hold |
16,000
| – | – | ﹤0.01% | 545 |
|
|
2019
Q1 | $7K | Hold |
16,000
| – | – | ﹤0.01% | 522 |
|
|
2018
Q4 | $8K | Hold |
16,000
| – | – | ﹤0.01% | 501 |
|
|
2018
Q3 | $8K | Hold |
16,000
| – | – | ﹤0.01% | 583 |
|
|
2018
Q2 | $8K | Hold |
16,000
| – | – | ﹤0.01% | 559 |
|
|
2018
Q1 | $7K | Hold |
16,000
| – | – | ﹤0.01% | 578 |
|
|
2017
Q4 | $6K | Hold |
16,000
| – | – | ﹤0.01% | 565 |
|
|
2017
Q3 | $6K | Hold |
16,000
| – | – | ﹤0.01% | 535 |
|
|
2017
Q2 | $6K | Hold |
16,000
| – | – | ﹤0.01% | 509 |
|
|
2017
Q1 | $7K | Hold |
16,000
| – | – | ﹤0.01% | 516 |
|
|
2016
Q4 | $6K | Hold |
16,000
| – | – | ﹤0.01% | 535 |
|
|
2016
Q3 | $4K | Hold |
16,000
| – | – | ﹤0.01% | 542 |
|
|
2016
Q2 | $4K | Hold |
16,000
| – | – | ﹤0.01% | 513 |
|
|
2016
Q1 | $2K | Hold |
16,000
| – | – | ﹤0.01% | 517 |
|
|
2015
Q4 | $2K | Hold |
16,000
| – | – | ﹤0.01% | 516 |
|
|
2015
Q3 | $3K | Hold |
16,000
| – | – | ﹤0.01% | 503 |
|
|
2015
Q2 | $11K | Hold |
16,000
| – | – | ﹤0.01% | 519 |
|
|
2015
Q1 | $11K | Hold |
16,000
| – | – | ﹤0.01% | 509 |
|
|
2014
Q4 | $13K | Hold |
16,000
| – | – | ﹤0.01% | 503 |
|
|
2014
Q3 | $7K | Hold |
16,000
| – | – | ﹤0.01% | 537 |
|
|
2014
Q2 | $8K | Buy |
+16,000
| New | +$7.74K | ﹤0.01% | 534 |
|
Moors & Cabot's GCVRZ Position: Q1 2020 in Review
Moors & Cabot sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 16,000 shares — an estimated $14K sold.
Moors & Cabot first reported a position in GCVRZ in Q2 2014 and held it in 23 quarters. The position peaked at $14K in Q4 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- Moors & Cabot reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- Moors & Cabot sold 16,000 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $14K.
- Moors & Cabot first reported a position in Sanofi Contingent Value Rights in Q2 2014 and held it in 23 quarters.
- Moors & Cabot's Sanofi Contingent Value Rights position peaked at $14K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on Moors & Cabot's 13F filing for Q1 2020, filed 12 May 2020.